NCT07171827View on ClinicalTrials.gov

Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions
Anti-CD30BrentuximabDoxorubicinVinblastineDacarbazineFrontlineAdvanced Classical Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine

Patients received Brentuximab Vedotin (BV)+ Doxorubicin, Vinblastine, and Dacarbazine (AVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.

DRUG

Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine

Patients received Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.

Trial Locations (1)

11795

Helwan University, Helwan

All Listed Sponsors
lead

Helwan University

OTHER